Update on Hepatitis C Treatment

, Clinical Instructor, UCLA School of Medicine, Los Angeles, California, and , Medical Director, Liver Transplantation, Cedars-Sinai Medical Center, Associate Professor of Medicine, UCLA School of Medicine, Los Angeles, California


February 15, 2001

In This Article

Future Trends

There has been continued interest in developing non-IFN-based therapies for HCV despite the promise of the pegylated IFNs. A recent study examined the role of human interleukin-10 in treating prior NRs with chronic HCV.[28] Although, HCV RNA remained detectable in all patients at the end of treatment,[25] 5 (23%) of the 22 treated patients had persistent ALT normalization at the end of follow-up. Future studies should determine whether combining interleukin-10 with other antiviral agents will increase efficacy in this setting. Interleukin-12 has also been evaluated as monotherapy, again without clear antiviral benefit.[29]

There is also increasing enthusiasm for targeting HCV molecular products. For example, ribozyme gene therapy has the potential to accurately degrade HCV RNA.[30] Human studies are anticipated.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.